Clinical Trial

A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This study will evaluate the safety, tolerability, and efficacy of engineered donor grafts ("OrcaGraft"/"Orca-Q") in participants undergoing allogeneic hematopoietic cell transplant (alloHCT) transplantation for hematologic malignancies.
Protocol Amendment History 18 amendments
This ClinicalTrials.gov record has been amended 18 times since 2019-01-10; most recent amendment 2026-06-29.
Status change: Available → Recruiting 2021-10-28
Status change: Recruiting → Available 2020-08-26
Status change: Not Yet Recruiting → Recruiting 2019-04-15
Trial Details
NCT Number NCT03802695
Lead Sponsor Orca Biosystems, Inc.
Conditions Acute Myeloid Leukemia, Myelodysplastic Syndromes, Mixed Phenotype Acute Leukemia, Acute Lymphoblastic Leukemia
Enrollment 300 participants
Start Date 2019-04-08
Primary Completion 2027-12 (estimated)
Study Completion 2027-12 (estimated)
Updated on ClinicalTrials.gov 2026-07-01